These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25519162)

  • 1. Evaluation of High-Dose Daptomycin Versus Vancomycin Alone or Combined with Clarithromycin or Rifampin Against Staphylococcus aureus and S. epidermidis in a Novel In Vitro PK/PD Model of Bacterial Biofilm.
    Hall Snyder AD; Vidaillac C; Rose W; McRoberts JP; Rybak MJ
    Infect Dis Ther; 2014 Dec; 4(1):51-65. PubMed ID: 25519162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
    Parra-Ruiz J; Vidaillac C; Rose WE; Rybak MJ
    Antimicrob Agents Chemother; 2010 Oct; 54(10):4329-34. PubMed ID: 20696880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.
    Barber KE; Smith JR; Ireland CE; Boles BR; Rose WE; Rybak MJ
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4497-503. PubMed ID: 25987623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic bactericidal effects of phage-enhanced antibiotic therapy against MRSA biofilms.
    Kunz Coyne AJ; Stamper K; Bleick C; Kebriaei R; Lehman SM; Rybak MJ
    Microbiol Spectr; 2024 Apr; 12(4):e0321223. PubMed ID: 38411110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Daptomycin Dose Exposure Alone or in Combination with β-Lactams or Rifampin against Vancomycin-Resistant Enterococci in an
    Jahanbakhsh S; Singh NB; Yim J; Kebriaei R; Smith JR; Lev K; Tran TT; Rose WE; Arias CA; Rybak MJ
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094136
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of Telavancin Alone and Combined with Ceftaroline or Rifampin against Methicillin-Resistant Staphylococcus aureus in an
    Jahanbakhsh S; Singh NB; Yim J; Rose WE; Rybak MJ
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides.
    Capone A; Cafiso V; Campanile F; Parisi G; Mariani B; Petrosillo N; Stefani S
    Eur J Clin Microbiol Infect Dis; 2016 Apr; 35(4):625-31. PubMed ID: 26815434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telavancin demonstrates activity against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to vancomycin, daptomycin, and linezolid in broth microdilution MIC and one-compartment pharmacokinetic/pharmacodynamic models.
    Smith JR; Barber KE; Hallesy J; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5529-34. PubMed ID: 26124162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Omadacycline Alone and in Combination with Rifampin against Staphylococcus aureus and Staphylococcus epidermidis in an
    Morrisette T; Stamper KC; Lev KL; Kebriaei R; Holger DJ; Abdul-Mutakabbir JC; Kunz Coyne AJ; Rybak MJ
    Antimicrob Agents Chemother; 2023 Jun; 67(6):e0131722. PubMed ID: 37222591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy of dalbavancin alone and with rifampicin against in vitro biofilms in a pharmacodynamic model with methicillin-resistant Staphylococcus aureus.
    El Haj C; Benavent E; Sierra Y; Soldevila L; Rigo-Bonnin R; Torrejón B; Gomez-Junyent J; Rosselló I; Murillo O
    Int J Antimicrob Agents; 2022 Oct; 60(4):106664. PubMed ID: 36002115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of linezolid or trimethoprim/sulfamethoxazole in combination with rifampicin as alternative oral treatments based on an in vitro pharmacodynamic model of staphylococcal biofilm.
    El Haj C; Murillo O; Ribera A; Lloberas N; Gómez-Junyent J; Tubau F; Fontova P; Cabellos C; Ariza J
    Int J Antimicrob Agents; 2018 Jun; 51(6):854-861. PubMed ID: 29374577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.
    Steed ME; Vidaillac C; Rybak MJ
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5187-92. PubMed ID: 20921318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.
    Leonard SN; Rybak MJ
    J Antimicrob Chemother; 2009 Jan; 63(1):155-60. PubMed ID: 18984644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
    Werth BJ; Barber KE; Ireland CE; Rybak MJ
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3177-81. PubMed ID: 24663016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model.
    Steed M; Vidaillac C; Rybak MJ
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3522-6. PubMed ID: 21576449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-clinical Impact of the Synergistic Mechanism of Daptomycin and Ceftaroline on Patients with Methicillin-resistant Staphylococcus aureus Bacteremia Infections.
    Eliazar J; Johnson T; Chbib C
    Curr Rev Clin Exp Pharmacol; 2021; 16(4):296-299. PubMed ID: 33423652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis.
    LaPlante KL; Woodmansee S
    Antimicrob Agents Chemother; 2009 Sep; 53(9):3880-6. PubMed ID: 19564363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Clinical Isolates Among Daptomycin-Naive Patients in Korea.
    Nam EY; Yang SJ; Kim ES; Cho JE; Park KH; Jung SI; Yoon N; Kim DM; Lee CS; Jang HC; Park Y; Lee KS; Kwak YG; Lee JH; Park SY; Hwang JH; Kim M; Song KH; Kim HB
    Microb Drug Resist; 2018 Jun; 24(5):534-541. PubMed ID: 29863982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daptomycin combinations as alternative therapies in experimental foreign-body infection caused by meticillin-susceptible Staphylococcus aureus.
    El Haj C; Murillo O; Ribera A; Vivas M; Garcia-Somoza D; Tubau F; Cabellos C; Cabo J; Ariza J
    Int J Antimicrob Agents; 2015 Aug; 46(2):189-95. PubMed ID: 26051988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro pharmacodynamics of human simulated exposures of ceftaroline and daptomycin against MRSA, hVISA, and VISA with and without prior vancomycin exposure.
    Bhalodi AA; Hagihara M; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2014; 58(2):672-7. PubMed ID: 24217694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.